Navigation Links
Tramiprosate (Alzhemed? preclinical results published in Neurobiology of Aging

Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) is pleased to announce that Neurobiology of Aging, one of the world's leading peer-reviewed medical journals in the fields of gerontology and neuroscience, has published an online version of a publication on the preclinical development of tramiprosate (3-amino-1-propanesulfonic acid; Alzhemed?, including efficacy results in a mouse model of brain amyloidosis. Tramiprosate (Alzhemed? represents a potential new class of therapeutic agent and is Neurochem's investigational product candidate for the treatment of Alzheimer's disease (AD). The results presented in this paper include the amyloid binding and neuroprotective characteristics of tramiprosate (Alzhemed? and provide evidence for the potential disease-modifying effect of this product candidate to slow or arrest the progression of AD.

While the paper issue of the publication will be available in a future issue of Neurobiology of Aging, an electronic version of the article entitled "Targeting soluble Aβ peptide with Tramiprosate for the treatment of brain amyloidosis" is already accessible online, and can be found at by searching for "tramiprosate".

Findings about tramiprosate (Alzhemed) include:

  • Tramiprosate (Alzhemed? binds preferentially to soluble Aβ peptide and maintains Aβ in a non-fibrillar form.
  • Tramiprosate (Alzhemed? decreases by 38% (p-value < 0.01) Aβ42-induced cell death in primary rat neuronal cell cultures.
  • Tramiprosate (Alzhemed? treatment in a transgenic mouse model of brain amyloidosis resulted in a dose-dependent reduction of over 60% of Aβ levels in plasma. There were significant decreases in brain levels of both soluble Aβ40 (30%; p-value of 0.014) and insoluble Aβ40 (31%; p-value of 0.035). Corresponding decreases of 25% (p-value of 0.033) and 22% (p-value of 0.029) were observed for the soluble and insoluble fractions of Aβ42 peptide, respecti vely.
  • Tramiprosate (Alzhemed? crosses the blood-brain-barrier to exert its activity with low toxicity in various animal species that were tested.

The presence of amyloid in the brain is one of the major histopathological characteristics of AD. The amyloid cascade hypothesis proposes that certain forms of Aβ peptide are toxic and causally related to the severity of AD. The Aβ-peptide is one of the most promising targets for the development of AD therapies.

"This scientific paper highlights the potential benefits of Alzhemed?" said Dr. Andreas Orfanos, Neurochem's Executive Vice President, Strategic Planning and Scientific Affairs. "These preclinical results indicate that AlzhemedTM binds preferentially to soluble amyloid β peptide, interferes with the amyloid cascade and reduces the associated toxicity. Accordingly, this product candidate is shown to impede key detrimental events normally associated with Alzheimer's disease and which are believed to lead to severe consequences in the brain of the affected individuals."

About tramiprosate (Alzhemed?
Tramiprosate (Alzhemed? is a small, orally-administered molecule known as an amyloid β antagonist, designed to cross the blood-brain-barrier, bind to soluble Aβ peptide and interfere with the amyloid cascade, thereby leading to the prevention or inhibition of amyloid deposition and the toxic effects of Aβ peptide in the brain.

About the Phase III Clinical Trials for tramiprosate (Alzhemed?
Neurochem is currently conducting a multi-center, randomized, double-blind, placebo-controlled and parallel-designed, 18-month Phase III clinical trial in 1,052 mild-to-moderate AD patients which is being carried out at close to 70 clinical sites across the United States and Canada. To date, 600 patients have already completed 12 months on study medication and the trial is scheduled to be completed by January 2007. All patients who complete the North American Phase III clinical trial will be offered the opportunity to receive tramiprosate (Alzhemed? in an open-label extension study.

Neurochem is also actively advancing an 18-month Phase III clinical trial for tramiprosate (Alzhemed? in Europe, which was initiated in September 2005. The ongoing European Phase III clinical trial, an international, multi-center, randomized, double-blind, placebo-controlled and parallel-designed study, is progressing on schedule and will investigate the safety, efficacy and disease-modifying potential of tramiprosate (Alzhemed?. Some 930 mild-to-moderate AD patients are expected to take part and enrollment is expected to be completed in the fall of 2006.

About Alzheimer's disease
Alzheimer's disease (AD) is a progressive form of dementia associated with specific brain pathologies. It impairs a person's cognitive and motor functions, their activities of daily living, alters the behaviour and gradually destroys the brain.

AD is the most common cause of dementia in our aging population. Almost 5 million individuals in the United States alone currently suffer from the condition. The U.S. Alzheimer's Association estimates that by 2025, over 22 million people worldwide will be afflicted.

According to a report commissioned by the U.S. Alzheimer's Association, AD costs American businesses approximately US$61 billion a year. That price tag includes US$24.6 billion for direct health care of Alzheimer's patients and US$36.5 billion to cover costs related to caregivers of AD patients, including lost productivity, absenteeism and worker replacement.


Source:Neurochem, Inc.

Related biology news :

1. Fatty spheres loaded with siRNA shrink ovarian cancer tumors in preclinical trial
2. Dual gene therapy suppresses lung cancer in preclinical test
3. Gene vaccine for Alzheimers disease shows promising results
4. Roche clinical trial registry and results database launched
5. Diabetic nerve therapy shows striking results
6. Neurologix announces positive results of gene therapy clinical trial in Parkinsons disease
7. New results validating Pall prion reduction filter disclosed at ISBT Congress
8. Combination therapy shows promising results in patients with advanced lung cancer
9. Vaccine for brain tumors shows promising results
10. Artificial cornea offers better results for infants, some blind patients
11. Encouraging results in pancreatic cancer research
Post Your Comments:

(Date:10/29/2015)... 29, 2015  The J. Craig Venter Institute (JCVI) ... Synthesis and Biosecurity: Lessons Learned and Options for the ... and Human Services guidance for synthetic biology providers has ... --> --> Synthetic biology ... potential to pose unique biosecurity threats. It now is ...
(Date:10/29/2015)... 2015 Today, LifeBEAM , a ... 2XU, a global leader in technical performance sports ... with advanced bio-sensing technology. The hat will allow ... key biometrics to improve overall training performance. As ... will bring together the most advanced technology, extensive ...
(Date:10/26/2015)... and LAS VEGAS , Oct. ... Labs , an innovator in modern authentication and a ... announced the launch of its latest version of the ... enabling organizations to use standards-based authentication that supports existing ... S3 Authentication Suite is ideal for organizations deploying customer-facing ...
Breaking Biology News(10 mins):
(Date:11/24/2015)... -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will be presenting ... on Wednesday, December 2 at 9:30 a.m. ET/6:30 a.m. ... will provide a corporate overview. th Annual Oppenheimer ... p.m. ET/10:00 a.m. PT . Jim Mazzola , vice ... overview. --> th Annual Oppenheimer Healthcare Conference in ...
(Date:11/24/2015)... ... November 24, 2015 , ... Copper is an essential micronutrient ... to proteins, copper is also toxic to cells. With a $1.3 million award ... will conduct a systematic study of copper in the bacteria Pseudomonas aeruginosa (P. ...
(Date:11/24/2015)... QUEBEC CITY , Nov. 24, 2015 /PRNewswire/ - ... the request of IIROC on behalf of the Toronto ... this news release there are no corporate developments that ... price. --> --> ... --> . --> Aeterna Zentaris ...
(Date:11/24/2015)... 2015 --> ... "Oligonucleotide Synthesis Market by Product & Services (Primer, Probe, ... DNA, RNAi), End-User (Research, Pharmaceutical & Biotech, Diagnostic Labs) ... market is expected to reach USD 1,918.6 Million by ... CAGR of 10.1% during the forecast period. ...
Breaking Biology Technology: